Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

STRIVE: Low-Dose Alteplase Ineffective in STEMI Patients With Large Thrombus

News Conference News TCT 2025

STRIVE: Low-Dose Alteplase Ineffective in STEMI Patients With Large Thrombus

Michael O'Riordan

October 28, 2025

The Skinny on Ultrathin DES: Meta-analysis Shows Some Long-term Advantages

News Conference News EuroPCR 2021

The Skinny on Ultrathin DES: Meta-analysis Shows Some Long-term Advantages

May 19, 2021

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

News Conference News CRT 2021

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

March 16, 2021

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

News Conference News ESC 2019

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

September 10, 2019

Drug-Coated Balloons in STEMI ‘Safe and Feasible’ in Specific Circumstances: REVELATION

News Conference News EuroPCR 2019

Drug-Coated Balloons in STEMI ‘Safe and Feasible’ in Specific Circumstances: REVELATION

May 22, 2019

Very EARLY Invasive Angiography in NSTE ACS Patients Reduces Risk of Recurrent Ischemia

News Conference News AHA 2018

Very EARLY Invasive Angiography in NSTE ACS Patients Reduces Risk of Recurrent Ischemia

Michael O'Riordan

November 11, 2018

Too Little, Too Late? Absorb BVS Shows Promising Results in STEMI Patients

News Conference News ESC 2018

Too Little, Too Late? Absorb BVS Shows Promising Results in STEMI Patients

Michael O'Riordan

August 28, 2018

ESC Updates Guidelines for Treating STEMI Patients

News Conference News ESC 2017

ESC Updates Guidelines for Treating STEMI Patients

Michael O'Riordan

August 27, 2017

News Conference News

PLATINUM: Novel Platinum-Chromium DES Equals Outcomes of Xience V-Promus

April 05, 2011

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.